Company Description

Kifa Therapeutics is a precision neuroscience company developing first-in-class therapies for genetically defined Parkinson’s disease. Their lead program targets the G2019S mutation in LRRK2—the most common genetic driver of familial PD—with unmatched selectivity, brain penetration, and translational promise.